Analysis of the implementation effect and influencing factors of multi-drug resistant tuberculosis management strategy in Guangzhou from 2020 to 2022

doi:10.3760/cma.j.issn.1007-1245.2024.16.004

International Medicine and Health Guidance News ›› 2024, Vol. 30 ›› Issue (16): 2653-2658.DOI: 10.3760/cma.j.issn.1007-1245.2024.16.004

• Special Column of Tuberculosis • Previous Articles Next Articles

Analysis of the implementation effect and influencing factors of multi-drug resistant tuberculosis management strategy in Guangzhou from 2020 to 2022

Yang Zilong¹, Chen Zeying², Wang Min², Feng Zhiyu², Zhang Hong², Kuang Haobin²

¹Graduate School of Guangzhou Medical University, Guangzhou 511436, China; ²Department of Tuberculosis, Guangzhou Chest Hospital, Key Laboratory of Tuberculosis Research in Guangzhou, State Key Laboratory of Respiratory Disease, Guangzhou 510095, China

Received:2024-01-25 Online:2024-08-15 Published:2024-09-03
Contact: Kuang Haobin, Email: kuanghaobin@163.com
Supported by:
Guangzhou Science and Technology Plan (2023B03J1303, 2023A03J0539); Major Project of Medical and Health Science and Technology in Guangzhou (20151A031002); Guangzhou Medical Key Discipline (2021-2023, Tuberculosis)

广州市2020年至2022年耐多药肺结核管理策略的实施效果以及影响因素分析

杨子龙¹ 陈泽莹² 汪敏² 冯治宇² 张宏² 邝浩斌²

¹广州医科大学研究生院，广州　511436；²广州市胸科医院结核内科广州市结核病研究重点实验室呼吸疾病国家重点实验室，广州　510095

通讯作者: 邝浩斌，Email：kuanghaobin@163.com
基金资助:
广州市科技计划（2023B03J1303、2023A03J0539）；广州市医药卫生科技重大项目（20151A031002）；广州市医学重点学科（2021-2023）结核病学

Abstract

Abstract:

¹Graduate School of Guangzhou Medical University, Guangzhou 511436, China; ²Department of Tuberculosis, Guangzhou Chest Hospital, Key Laboratory of Tuberculosis Research in Guangzhou, State Key Laboratory of Respiratory Disease, Guangzhou 510095, China

Key words:

Multi-drug resistant tuberculosis, Treatment outcomes, Risk factors

摘要：

¹广州医科大学研究生院，广州　511436；²广州市胸科医院结核内科广州市结核病研究重点实验室呼吸疾病国家重点实验室，广州　510095

关键词:

耐多药肺结核, 治疗转归, 影响因素

Yang Zilong, Chen Zeying, Wang Min, Feng Zhiyu, Zhang Hong, Kuang Haobin.

Analysis of the implementation effect and influencing factors of multi-drug resistant tuberculosis management strategy in Guangzhou from 2020 to 2022 [J]. International Medicine and Health Guidance News, 2024, 30(16): 2653-2658.

杨子龙陈泽莹汪敏冯治宇张宏邝浩斌.

广州市2020年至2022年耐多药肺结核管理策略的实施效果以及影响因素分析 [J]. 国际医药卫生导报, 2024, 30(16): 2653-2658.

References

[1] World Health Organization. Global tuberculosis report 2022[R/OL]. Geneva: World Health Organization. https://www.who.int/teams/global-tuberculosis-programme/TB-reports/global-tuberculosis-report-2022.
[2] Dheda K, Mirzayev F, Cirillo DM, et al. Multidrug-resistant tuberculosis[J]. Nat Rev Dis Primers, 2024, 10(1):22. DOI: 10.1038/s41572-024-00504-2.
[3] 律彤,杨云斌,潘颖,等.云南省利福平耐药肺结核患者经济负担现状及影响因素分析[J].中国防痨杂志,2023,45(11):1031-1037.DOI:10.19982/j.issn.1000-6621.20230235.
[4] 顾天成,李恒.两部门印发关于进一步加强耐药结核病防治工作通知[N/OL]. 2023-2-24. https://www.gov.cn/xinwen/2023-02/24/content_5743061.htm.
[5] 邝浩斌,谢育红,冯治宇,等.2014-2019年广州市耐多药肺结核管理策略实施效果分析[J].中国防痨杂志,2021,43(2):113-118.DOI:10.3969/j.issn.1000-6621.2021.02.003.
[6] 广州市卫生健康委员会,广州市财政局.广州市结核病防治经费管理办法(2022年版)[EB].(2022-07-21)[2024-01-24].
[7] World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update[R]. Geneva: World Health Organization, 2022.
[8] 中华医学会结核病学分会.中国耐多药和利福平耐药结核病治疗专家共识(2019年版)[J].中华结核和呼吸杂志,2019,42(10):733-749.DOI:10.3760/cma.j.issn.1001- 0939.2019.10.006.
[9] 国家卫生健康委员会办公厅.国家卫生健康委办公厅关于印发中国结核病预防控制工作技术规范(2020年版)的通知[A/0L].(2020-04-02)[2020.06-10]. http://tb.chinacdc.cn/ggl/202004/P020200414515703939844.pdf.
[10] 孙秀香,贺军宁,王鹏雁.共情护理联合多维度健康教育指导对肺结核患者的影响[J].国际医药卫生导报,2024,30(1):160-163.DOI:10.3760/cma.j.issn.1007-1245.2024.01.033.
[11] 伍小英,江坤洪,何刚,等.广州市海珠区重点人群结核病筛查情况分析[J].国际医药卫生导报,2022,28(2):223-228.DOI:10.3760/cma.j.issn.1007-1245.2022.02.019.
[12] Zhang S, Qiu L, Wu D, et al. Predictors for treatment outcomes in patients with multi-drug resistant tuberculosis - China, 2018-2020[J]. China CDC Wkly, 2022, 4(41):907-911. DOI: 10.46234/ccdcw2022.187.
[13] 李硕兰,李明武,李光妹,等.中国耐多药肺结核不良治疗转归影响因素的Meta分析[J].中国防痨杂志,2022,44(12):1303-1313.DOI:10.19982/j.issn.1000-6621.20220212.
[14] 石文卉,初乃惠.耐药肺结核患者氟喹诺酮类药物耐药情况及影响因素[J].中国防痨杂志,2021,43(9):905-909.DOI:10.3969/j.issn.1000-6621.2021.09.009.
[15] 严菁敏,陈莹,于洁,等.基于LASSO-logistic回归的TB/HIV患者抗结核治疗结局影响因素研究[J].现代预防医学,2023,50(22):4039-4045,4051.DOI:10.20043/j.cnki.MPM.202306338.
[16] 薛剑航,曹红,李露,等.308例耐多药肺结核患者的治疗转归及影响因素分析[J].结核与肺部疾病杂志,2024,5(1):44-50.DOI:10.19983/j.issn.2096-8493.20230085.
[17] 李京,高媛,逯嘉,等.四川省肺结核患者2年内复发情况及影响因素分析[J].中国防痨杂志,2023,45(11):1038-1044.DOI:10.19982/j.issn.1000-6621.20230193.
[18] Adane HT, Howe RC, Wassie L, et al. Diabetes mellitus is associated with an increased risk of unsuccessful treatment outcomes among drug-susceptible tuberculosis patients in Ethiopia: a prospective health facility-based study[J]. J Clin Tuberc Other Mycobact Dis, 2023, 31:100368. DOI: 10.1016/j.jctube.2023.100368.
[19] Huangfu P, Ugarte-Gil C, Golub J, et al. The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis[J]. Int J Tuberc Lung Dis, 2019, 23(7):783-796. DOI: 10.5588/ijtld.18.0433.
[20] Tegegne BS, Mengesha MM, Teferra AA, et al. Association between diabetes mellitus and multi-drug-resistant tuberculosis: evidence from a systematic review and meta-analysis[J]. Syst Rev, 2018, 7(1):161. DOI: 10.1186/s13643-018-0828-0.
[21] Alkabab Y, Warkentin J, Cummins J, et al. Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus[J]. Int J Tuberc Lung Dis, 2023, 27(2):135-139. DOI: 10.5588/ijtld.22.0448.
[22] Critchley JA, Restrepo BI, Ronacher K, et al. Defining a research agenda to address the converging epidemics of tuberculosis and diabetes: part 1: epidemiology and clinical management[J]. Chest, 2017, 152(1):165-173. DOI: 10.1016/j.chest.2017.04.155.
[23] Nasiri MJ, Zangiabadian M, Arabpour E, et al. Delamanid-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis[J]. Int J Infect Dis, 2022, 124Suppl 1(Suppl 1):S90-S103. DOI: 10.1016/j.ijid.2022.02.043.
[24] Huerga H, Khan U, Bastard M, et al. Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid, and other second-line drugs[J]. Clin Infect Dis, 2022, 75(8):1307-1314. DOI: 10.1093/cid/ciac176.
[25] Hatami H, Sotgiu G, Bostanghadiri N, et al. Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis[J]. J Bras Pneumol, 2022, 48(2):e20210384. DOI: 10.36416/1806-3756/e20210384.
[26] Franke MF, Khan P, Hewison C, et al. Culture conversion in patients treated with bedaquiline and/or delamanid. A prospective multicountry study[J]. Am J Respir Crit Care Med, 2021, 203(1):111-119. DOI: 10.1164/rccm.202001- 0135OC.
[27] Seung KJ, Khan P, Franke MF, et al. Culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis[J]. Clin Infect Dis, 2020, 71(2):415-418. DOI: 10.1093/cid/ciz1084.
[28] Saluzzo F, Adepoju VA, Duarte R, et al. Treatment-shortening regimens for tuberculosis: updates and future priorities[J]. Breathe (Sheff), 2023, 19(3):230028. DOI: 10.1183/20734735.0028-2023.
[29] 张亚萍,牛亚燕,唐佩军.贝达喹啉治疗特殊人群耐药结核病的安全性与有效性研究进展[J].中华结核和呼吸杂志,2023,46(6):619-624.DOI:10.3760/cma.j.cn112147- 20230103-00003.
[30] 张亚萍,唐佩军.德拉马尼治疗特殊人群耐药结核病的安全性与有效性的研究进展[J].中华传染病杂志,2023,41(10):678-682.DOI:10.3760/cma.j.cn311365-20230323-00083.
[31] Kokebu DM, Ahmed S, Moodliar R, et al. Failure or relapse predictors for the STREAM stage 1 short regimen for RR-TB[J]. Int J Tuberc Lung Dis, 2022, 26(8):753-759. DOI: 10.5588/ijtld.22.0073.

Analysis of the implementation effect and influencing factors of multi-drug resistant tuberculosis management strategy in Guangzhou from 2020 to 2022

广州市2020年至2022年耐多药肺结核管理策略的实施效果以及影响因素分析

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	Song Yunhong, Liu Yanan, Zhang Zongli. Risk factor analysis of coronary heart disease in elderly patients with hypertension [J]. International Medicine and Health Guidance News, 2024, 30(8): 1253-1258.
[2]	Gao Linlin, Sui Yun, Wang Lixin. Risk factors of gastrointestinal adverse reactions in patients with T2DM treated with metformin [J]. International Medicine and Health Guidance News, 2024, 30(7): 1176-1181.
[3]	Wang Le, Chen Yingli, Zhang Kailu, Zhang Yinfu, Du Ruini, Gao Wei. Risk factors for plasmapheresis or dialysis in non-diabetic patients with kidney transplantation [J]. International Medicine and Health Guidance News, 2024, 30(6): 953-957.
[4]	Zhu Yushu, Gao Junyan, Wang Fudong, Jiang Lijun, Wu Mingfu. Analysis of risk factors associated with blood transfusion in preterm infants with gestational age <32 weeks [J]. International Medicine and Health Guidance News, 2024, 30(2): 258-262.
[5]	Mei Chuangchuang, Cai Donghao, Li Xiaojun. Risk factors for MRSA infection in patients with cerebral infarction and establishment of a clinical prediction model [J]. International Medicine and Health Guidance News, 2024, 30(17): 2888-2894.
[6]	Wang Wenjuan, Wang Shifeng, Chen Peng, Cao Xue. Analysis of risk factors for early neurological deterioration in patients with perforating artery atherosclerosis treated by intravenous thrombolysis with ateplase [J]. International Medicine and Health Guidance News, 2024, 30(17): 2916-2921.
[7]	Li Heng, Jiang Shijie, Lian Peng, Zhang Hui. Analysis on 60 cases of different superior mesenteric artery ischemic diseases [J]. International Medicine and Health Guidance News, 2024, 30(17): 2941-2945.
[8]	Yang Liping, Si Yi, Ren Guangzhuo. Risk factors and intervention strategies of early postoperative complications in elderly patients with gastric cancer undergoing minimally invasive radical gastrectomy [J]. International Medicine and Health Guidance News, 2024, 30(16): 2806-2810.
[9]	Gao Yiwei, Ma Yingying, Zhang Man, Chu Weihong. Risk factors for cardiac damage in children with Kawasaki disease [J]. International Medicine and Health Guidance News, 2024, 30(14): 2317-2321.
[10]	Zhang Zhenglu, Ning Jie, Gao Ruijiang, Liu Guojuan, Wu Yihan. Incidence and risk factors of carotid artery plaque in some community in Hohhot [J]. International Medicine and Health Guidance News, 2024, 30(13): 2169-2174.
[11]	Shao Shuqin, Liu Xiaoming. Risk factors of cognitive dysfunction in patients taking peritoneal dialysis and establishment of a predictive model [J]. International Medicine and Health Guidance News, 2024, 30(13): 2214-2219.
[12]	Wang Sujuan, Hai Yunting, Lu Xuegeng, Wang Xue, Qu Lin. Risk factors of catheter-related bloodstream infection in ICU patients and construction of risk prediction nomogram model [J]. International Medicine and Health Guidance News, 2024, 30(12): 1982-1987.
[13]	Li Xinmeng, Liu Qianqian, Liu Yunqi. Risk factors and delay strategies for progression of chronic kidney disease [J]. International Medicine and Health Guidance News, 2024, 30(11): 1766-1770.
[14]	Yu Hongjin, Yang Wenbin, Yan Yu, Liu Xingguo. Construction of a nomogram prediction model for delirium in patients with open and comminuted fractures of the limbs after trauma [J]. International Medicine and Health Guidance News, 2024, 30(10): 1632-1637.
[15]	Zhao Yidi, Liang Hao , Chen Muxin , Wei Lin . Body composition and frailty risk: a meta-analysis [J]. International Medicine and Health Guidance News, 2024, 30(1): 8-14.